CStone Pharmaceuticals appoints new independent director, Ms. Fang Xie

CStone Pharmaceuticals has appointed Ms. Fang Xie as an independent non-executive director, effective November 1, 2025. Ms. Xie will also chair the audit committee and serve as a member of the compensation, nomination, and investment committees. She brings over 30 years of experience in operational finance and management consulting, having held key roles at ZTO Express (Cayman) Inc., Seres Capital, and Global Logistic Properties, where she led its initial public offering on the Singapore Stock Exchange. She will receive a director's remuneration of $60,000 per annum.

Concurrently, Ms. Yip Betty Ho has resigned as an independent non-executive director, chairperson of the audit committee, and a member of the compensation, nomination, strategy, and investment committees, effective October 31, 2025, due to personal commitments. The company expressed gratitude for her contributions.

Following these changes, Ms. Xie will hold office until the next annual general meeting, where she will be eligible for re-election for a three-year term. The board confirmed Ms. Xie's independence, noting no past or present financial interest in the company or its subsidiaries.